The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interrogating MEK inhibition in a KRAS-mutant lung cancer patient-derived xenograft (PDX) resource.
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - Apton Biosystems; AstraZeneca; MolecularMD
Research Funding - Boehringer Ingelheim
Travel, Accommodations, Expenses - Guardant Health
 
Jonathan Riess
Honoraria - Roche/Genentech
Consulting or Advisory Role - Celgene
Research Funding - Merck (Inst); Millennium (Inst); Novartis (Inst); Onconova Therapeutics
Travel, Accommodations, Expenses - Roche/Genentech
 
Rebekah A Burich
No Relationships to Disclose
 
Mingshan Cheng
No Relationships to Disclose
 
Hongyuan Yang
No Relationships to Disclose
 
Yu Li
No Relationships to Disclose
 
Susan D. Airhart
No Relationships to Disclose
 
Carol J. Bult
No Relationships to Disclose
 
James G. Keck
No Relationships to Disclose
 
Joel H Graber
No Relationships to Disclose
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer